Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 3Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 17Gastrointestinal 5CNS 4Thoracic 3Other solid neoplasm 3Plasma cell 1Gynecologic 1Dermatologic 1Breast 1

Conditions

Melanoma 424Carcinoma, Non-Small-Cell Lung 92Neoplasm Metastasis 69Neoplasms 60Carcinoma, Renal Cell 54Lymphoma, T-Cell, Cutaneous 52Ovarian Neoplasms 46Squamous Cell Carcinoma of Head and Neck 42Breast Neoplasms 40Colorectal Neoplasms 38Stomach Neoplasms 37Skin Neoplasms 35Lymphoma 32Mycosis Fungoides 31Carcinoma, Merkel Cell 31Uveal Melanoma 30Triple Negative Breast Neoplasms 29Lung Neoplasms 29Sezary Syndrome 28Lymphoma, Non-Hodgkin 28Lymphoma, Follicular 27Hodgkin Disease 27Pancreatic Neoplasms 26Uterine Cervical Neoplasms 25Sarcoma 25Lymphoma, Large B-Cell, Diffuse 24Leukemia, Lymphocytic, Chronic, B-Cell 24Lymphoma, B-Cell, Marginal Zone 23Carcinoma, Hepatocellular 23Lymphoma, Mantle-Cell 22

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Neurofibrosarcoma × Dermatologic × Clear all
NCT03611868 2025-08-07

A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors

Ascentage Pharma Group Inc.

Phase 1/2 Active not recruiting
230 enrolled
DermatologicSarcoma

Uveal Melanoma, Melanoma, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡